WO2019245512A3 - Combinaison comprenant du fingolimod et au moins un agent anti-épileptique - Google Patents

Combinaison comprenant du fingolimod et au moins un agent anti-épileptique Download PDF

Info

Publication number
WO2019245512A3
WO2019245512A3 PCT/TR2019/050471 TR2019050471W WO2019245512A3 WO 2019245512 A3 WO2019245512 A3 WO 2019245512A3 TR 2019050471 W TR2019050471 W TR 2019050471W WO 2019245512 A3 WO2019245512 A3 WO 2019245512A3
Authority
WO
WIPO (PCT)
Prior art keywords
fingolimod
combination
epileptic agent
epileptic
agent
Prior art date
Application number
PCT/TR2019/050471
Other languages
English (en)
Other versions
WO2019245512A2 (fr
Inventor
Ali Turkyilmaz
Merve PEKER
Emine TUNCAY
Erkin Ozturk
Muge ULUSOY BOZYEL
Yavuz Dedeoglu
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP19822106.1A priority Critical patent/EP3810274A4/fr
Publication of WO2019245512A2 publication Critical patent/WO2019245512A2/fr
Publication of WO2019245512A3 publication Critical patent/WO2019245512A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique comprenant du fingolimod ou un sel pharmaceutiquement acceptable de celui-ci et au moins un agent anti-épileptique.
PCT/TR2019/050471 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique WO2019245512A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19822106.1A EP3810274A4 (fr) 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201808815 2018-06-21
TR2018/08815 2018-06-21

Publications (2)

Publication Number Publication Date
WO2019245512A2 WO2019245512A2 (fr) 2019-12-26
WO2019245512A3 true WO2019245512A3 (fr) 2020-06-04

Family

ID=68983746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050471 WO2019245512A2 (fr) 2018-06-21 2019-06-19 Combinaison comprenant du fingolimod et au moins un agent anti-épileptique

Country Status (2)

Country Link
EP (1) EP3810274A4 (fr)
WO (1) WO2019245512A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074062A1 (es) * 2008-10-31 2010-12-22 Lexicon Pharmaceuticals Inc Agonistas del receptor s1p para el tratamiento de la malaria cerebral y forma farmaceutica
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140308244A1 (en) * 2011-08-08 2014-10-16 The Board Of Trustees Of The Leland Stanford Junior University Combination Therapy for Treatment of Inflammatory Demyelinating Disease
WO2018082814A1 (fr) * 2016-11-07 2018-05-11 Metriopharm Ag Utilisation de 5-amino-2,3-dihydro-1,4-phthalazinedione dans le traitement de la sclérose en plaques progressive chronique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
METIN, S. K. ET AL.: "The effect of pregabalin and methylcobalamin combination on the chronic postthoracotomy pain syndrome", THE ANNALS OF THORACIC SURGERY, vol. 103, no. 4, 2017, pages 1109 - 1113, XP029956788, DOI: 10.1016/j.athoracsur.2016.09.031 *
MIMENZA ALVARADO, A. ET AL.: "Clinical trial assessing the efficacy of gabapentin plus B complex (B 1/B 12) versus pregabalin for treating painful diabetic neuropathy", JOURNAL OF DIABETES RESEARCH, 2016, XP055711547 *

Also Published As

Publication number Publication date
EP3810274A4 (fr) 2022-03-16
WO2019245512A2 (fr) 2019-12-26
EP3810274A2 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
EP4233846A3 (fr) Formulations pharmaceutiques
HRP20221158T1 (hr) Sredstva za izazivanje apoptoze
WO2016064082A3 (fr) Nouveau dérivé aminoalkyle benzothiazépine et son utilisation
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
IL283539A (en) 3,3-difluoroallylamines or their salts and pharmaceutical preparations containing them
EP4041734A4 (fr) Nouveaux dérivés ayant une fraction 1,2,3,4-tétrahydronaphtalène ou un sel pharmaceutiquement acceptable de ceux-ci et compositions pharmaceutiques les comprenant
WO2016205738A3 (fr) Systèmes d'administration pour la libération contrôlée de médicaments
USD946751S1 (en) Dual-ended swab
EP3698649A4 (fr) Agent destiné à la prévention ou à l'atténuation de la maladie d'alzheimer
WO2016196124A3 (fr) Promédicaments comprenant un lieur de pyroglutamate
WO2019203771A3 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
WO2019194773A3 (fr) Combinaison contenant de la linagliptine et de la metformine
EP3539978A4 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
WO2020122838A3 (fr) Combinaison comprenant un agent de sclérose en plaques et au moins un agent anti-épileptique
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
WO2016163818A3 (fr) Composition pharmaceutique pour prévenir ou traiter l'arthrite ou une maladie inflammatoire contenant du 2-méthoxy-4-(3-(4-méthoxyphényl)propyl-1-én-1-yl)phénol en tant que principe actif
WO2019245512A3 (fr) Combinaison comprenant du fingolimod et au moins un agent anti-épileptique
WO2019203753A3 (fr) Combinaison pharmaceutique comprenant de la dapoxétine, un inhibiteur de phosphodiestérase de type 5 et un agent antiémétique
WO2020018053A3 (fr) Comprimé comprenant du dasatinib
WO2020139238A3 (fr) Combinaisons pharmaceutiques comprenant du fingolimod et un spasmolytique
IL282999A (en) 4,3,1-oxadiazolone compound and drug
WO2019209217A3 (fr) Formulations à libération modifiée de flurbiprofène
WO2020139237A3 (fr) Formulation de comprimé bicouche d'atorvastatine calcique et d'ézétimibe
WO2020159159A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles du stockage lysosomal
IL264538B2 (en) A new use of n,n-bis-2-mercaptoethyl isophthalamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19822106

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019822106

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019822106

Country of ref document: EP

Effective date: 20210121

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19822106

Country of ref document: EP

Kind code of ref document: A2